Literature DB >> 21785550

Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.

Peter J Hughes, Erika Cretton-Scott, Ami Teague, Terri M Wensel.   

Abstract

Entities:  

Keywords:  HIV; human immunodeficiency virus; protease inhibitor

Year:  2011        PMID： 21785550      PMCID： PMC3138376     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  59 in total

Review 1.  HIV-1 protease: mechanism and drug discovery.

Authors:  Ashraf Brik; Chi-Huey Wong
Journal:  Org Biomol Chem       Date:  2003-01-07       Impact factor: 3.876

2.  Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

Authors:  Charles B Hicks; Edwin DeJesus; Louis M Sloan; Michael G Sension; David A Wohl; Qiming Liao; Lisa L Ross; Gary E Pakes; Keith A Pappa; C Tracey Lancaster
Journal:  AIDS Res Hum Retroviruses       Date:  2009-04       Impact factor: 2.205

3.  A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

Authors:  Ulrik B Dragsted; Jan Gerstoft; Mike Youle; Zoe Fox; Marcello Losso; Jorge Benetucci; Dushyantha T Jayaweera; Armin Rieger; Johan N Bruun; Antonella Castagna; Brian Gazzard; Sharon Walmsley; Andrew Hill; Jens D Lundgren
Journal:  Antivir Ther       Date:  2005

4.  Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.

Authors:  M A Boyd; U Siangphoe; K Ruxrungtham; C J Duncombe; M Stek; J M A Lange; D A Cooper; P Phanuphak
Journal:  HIV Med       Date:  2005-11       Impact factor: 3.180

5.  Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Authors:  Vincent Soriano; Pilar García-Gasco; Eugenia Vispo; Andrés Ruiz-Sancho; Francisco Blanco; Luz Martín-Carbonero; Sonia Rodríguez-Novoa; Judit Morello; Carmen de Mendoza; Pablo Rivas; Pablo Barreiro; Juan González-Lahoz
Journal:  J Antimicrob Chemother       Date:  2007-11-13       Impact factor: 5.790

6.  Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

Authors:  Sharon Walmsley; Anchalee Avihingsanon; Jihad Slim; Douglas J Ward; Kiat Ruxrungtham; Jason Brunetta; U Fritz Bredeek; Dushyantha Jayaweera; Carol Jean Guittari; Peter Larson; Malte Schutz; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

7.  Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.

Authors:  Maria Mercedes Santoro; Ada Bertoli; Patrizia Lorenzini; Adriano Lazzarin; Roberto Esposito; Giampiero Carosi; Giovanni Di Perri; Gaetano Filice; Mauro Moroni; Giuliano Rizzardini; Pietro Caramello; Renato Maserati; Pasquale Narciso; Antonietta Cargnel; Andrea Antinori; Carlo Federico Perno
Journal:  AIDS Patient Care STDS       Date:  2008-01       Impact factor: 5.078

8.  Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.

Authors:  Sharon L Walmsley; Laurent Cotte; Stefano Rusconi; Douglas J Ward; Charles B Hicks; Ulrich Meier; Hernan Valdez; Charles Ab Boucher
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

9.  Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.

Authors:  Martin Markowitz; Leonard N Slater; Robert Schwartz; Powel H Kazanjian; Bruce Hathaway; David Wheeler; Mitchell Goldman; Dietmar Neubacher; Douglas Mayers; Hernan Valdez; Scott McCallister
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-01       Impact factor: 3.731

10.  Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Authors:  Jean-François Delfraissy; Philippe Flandre; Constance Delaugerre; Jade Ghosn; Andrzej Horban; Pierre-Marie Girard; Michael Norton; Christine Rouzioux; Anne-Marie Taburet; Isabelle Cohen-Codar; Philippe Ngo Van; Jean-Pierre Chauvin
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177
View more
  13 in total

1.  Why strategies to control Leishmania spp. multiplication based on the use of proteinase inhibitors should consider multiple targets and not only a single enzyme.

Authors:  Carlos Roberto Alves; Bernardo Acácio Santini Pereira; Mariana Silva-Almeida; Franklin Souza da Silva
Journal:  J Mol Model       Date:  2014-10-09       Impact factor: 1.810

2.  Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.

Authors:  Arun K Ghosh; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Heather L Osswald; Cuthbert D Martyr; Manabu Aoki; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Haydar Bulut; Debananda Das; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2017-04-18       Impact factor: 7.446

3.  Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Authors:  Arun K Ghosh; Jacqueline N Williams; Rachel Y Ho; Hannah M Simpson; Shin-Ichiro Hattori; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-10-24       Impact factor: 7.446

4.  Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Authors:  Arun K Ghosh; Prasanth R Nyalapatla; Satish Kovela; Kalapala Venkateswara Rao; Margherita Brindisi; Heather L Osswald; Masayuki Amano; Manabu Aoki; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-05-15       Impact factor: 7.446

5.  Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.

Authors:  Abhirup Mandal; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2016-08-16       Impact factor: 5.875

6.  Impact of body fat changes in mediating the effects of antiretroviral therapy on blood pressure in HIV-infected persons in a sub-Saharan African setting.

Authors:  Chidozie U Nduka; Olalekan A Uthman; Peter K Kimani; Abraham O Malu; Saverio Stranges
Journal:  Infect Dis Poverty       Date:  2016-06-01       Impact factor: 4.520

7.  Antioxidant modulation of nevirapine induced hepatotoxicity in rats.

Authors:  Olufunsho Awodele; Temidayo Popoola; Kunle Rotimi; Victor Ikumawoyi; Wahab Okunowo
Journal:  Interdiscip Toxicol       Date:  2015-03

Review 8.  Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy.

Authors:  Adnan Bashir Bhatti; Muhammad Usman; Venkataramana Kandi
Journal:  Cureus       Date:  2016-03-01

9.  Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.

Authors:  Sanelisiwe Nzuza; Sindiswa Zondi; Peter M O Owira
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

Review 10.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.